cpl409116
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 8, 2020 (NCT04670757)
Timeline
Indications
Mechanism of action
- Rho-associated protein kinase 1INHIBITOR
ROCK1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05374785 | Phase 2 | May 1, 2022 | Celon Pharma SA, Government of Poland |
| NCT04670757 | Phase 1 | Dec 8, 2020 | Celon Pharma SA, Government of Poland |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celon Pharma SA | For profit | 2 | 2 | 2 | 2020 |
| Government of Poland | Government | 2 | 0 | 2 | 2020 |
2 organizations
Page 1 / 1